Market capitalization | $35.09m |
Enterprise Value | $-36.96m |
P/E (TTM) P/E ratio | negative |
P/B ratio (TTM) P/B ratio | 0.51 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-42.01m |
Cash position | $103.07m |
EPS (TTM) EPS | $-0.81 |
P/E forward | negative |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Elevation Oncology Inc forecast:
7 Analysts have issued a Elevation Oncology Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.03 -0.03 |
25%
25%
|
|
EBITDA | -42 -42 |
18%
18%
|
EBIT (Operating Income) EBIT | -42 -42 |
18%
18%
|
Net Profit | -42 -42 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Elevation Oncology, Inc. operates as a precision oncology company. It focuses on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The firm’s program is focused on patients with advanced solid tumors harboring an NRG1 fusion. The company was founded by Shawn M. Leland in 2019 and is headquartered in New York, NY.
Head office | United States |
CEO | Joseph Ferra |
Employees | 29 |
Founded | 2019 |
Website | www.elevationoncology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.